Ariceum Therapeutics to Present New Preclinical Data at SNMMI 2024
Ariceum Therapeutics, a biotech company specializing in radiopharmaceuticals for diagnosing and treating challenging cancers, has announced compelling new findings on its somatostatin receptor 2 (SST2) antagonist, SS0110 (satoreotide). These results will be showcased at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, held from June 8-11, 2024, in Toronto, Canada.
At the core of the presentation is a comparative study between satoreotide and the SST2-targeting agonist, 225Ac-DOTATATE. The data reveal that single doses of 20 MBq 177Lu-satoreotide or 30 kBq 225Ac-satoreotide demonstrate significantly superior efficacy compared to a single dose of 30 kBq 225Ac-DOTATATE. Remarkably, the 30 kBq dose of 225Ac-satoreotide induced complete tumor regression in the NCI-H69 murine model, a result not achieved with equal or higher doses of 225Ac-DOTATATE.
This elevated efficacy is attributed to satoreotide’s higher tumor uptake and longer retention, which results in better tumor-to-background and tumor-to-kidney ratios. These properties translate into higher pre-clinical effectiveness, especially when labeled with isotopes such as 225Ac and 177Lu. The potential for satoreotide to outperform SST2-targeting agonists underscores its promise for clinical development in treating SST2-positive tumors, including Small Cell Lung Cancer (SCLC) and Merkel Cell Carcinoma (MCC).
Manfred Rüdiger, CEO of Ariceum Therapeutics, highlighted the significance of these findings, stating: "Satoreotide shows great promise as a transformative treatment for SCLC and MCC. Its potency surpasses that of DOTATATE, regardless of the isotope used, affirming the superiority of SST2 antagonists over agonists. We're eager to present our findings at the SNMMI meeting."
The detailed findings will be presented by Anika Jaekel, the Senior Director and Head of Translational Biology and Non-Clinical Pharmacology at Ariceum Therapeutics. The session titled "[225Ac]Ac-SSO110 and [177Lu]Lu-SSO110 demonstrate significantly better efficacy than [225Ac]Ac-DOTA-TATE in the treatment of SST2-positive tumor xenografts" will take place on Monday, June 10, 2024, from 10:00 - 11:15 DST.
Ariceum Therapeutics, founded in 2021, focuses on developing targeted systemic radiopharmaceutical products for diagnosing and treating neuroendocrine and other aggressive cancers. Their lead product, 177Lu-satoreotide tetraxetan ("Satoreotide"), targets the somatostatin type 2 (SSTR2) receptor, overexpressed in neuroendocrine tumors (NETs) and aggressive cancers like SCLC and MCC. These cancers typically have few treatment options and poor prognosis. Satoreotide is being developed as a theranostic pair, combining diagnostic imaging with targeted radionuclide therapy.
In addition to satoreotide, Ariceum is developing a radiolabeled PARP-inhibitor (ATT001), expected to enter clinical stages in 2024. ATT001 was acquired through the acquisition of Theragnostics Ltd, completed in June 2023.
Based in Berlin, with operations across Germany, Switzerland, Australia, the UK, and the USA, Ariceum is led by an experienced management team and backed by notable investors like EQT Life Sciences, HealthCap, Pureos Bioventures, Andera Partners, and Earlybird Venture Capital.
The SNMMI, headquartered in Reston, VA, is a nonprofit organization dedicated to advancing nuclear medicine and molecular imaging science, technology, and practices. Ariceum’s presentation at their annual meeting highlights the company’s ongoing commitment to pioneering treatments for hard-to-treat cancers, offering new hope in the fight against these challenging diseases.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
